Adventis Group PLC
05 December 2007
For release 7.00am 5th December 2007
Adventis Group plc (ATG/L)
'Formation of New Market-Leading Healthcare Services Provider - Adventis Health
Limited'
Adventis Group plc ('Adventis' or the 'Company'), the AIM-quoted full service
multimedia marketing and advertising agency, announces that it has recently
consolidated its three healthcare creative and medical education agencies, which
formed the Adventis Healthcare services division, namely Affiniti Advertising,
Roundhouse HealthAd and LeapFrog, into a new trading entity which will be
branded Adventis Health Limited ('Adventis Health').
Adventis Health will be run by three directors, namely Stuart Tennant, Tim
Schofield and Kevin McGetrick. All three have extensive healthcare and
management experience.
This consolidation of Adventis Group's strength in the healthcare sector follows
on from the former division's earlier move into centralised premises in
Beaconsfield, near to the M25 and M40, in August 2007 in addition to the
Company's existing offices in Hertford and Central London.
Adventis Health, whose clients include, GSK, Pfizer, MSD, Roche, Novartis,
Boehringer Ingelheim, Allergan, Baxter and Merck Serono, provides a range of
highly skilled advertising and marketing services as well as medical education &
PR programmes to the healthcare industry, targeted at both healthcare
professionals and patients, in order to improve clients' sales and brand
awareness.
The Company anticipates that the formation of Adventis Health will create one of
the industry's top five pharmaceutical industry service providers with a
formidable, award-winning team of over 60 employees. The enlarged Healthcare
services operations will have the capability to provide a complete range of
integrated marketing services, from medical education, to advertising, to new
media. It will also provide the opportunity for an increased level of
cross-selling and the ability to provide multinational clients with a greater
local understanding of target markets.
Charles Phillpot, Chief Executive of Adventis Group plc, commented:
'The creation of this new platform servicing the healthcare sector is a
fantastic opportunity to leverage to the full our expertise in this arena. We
will now be one of the few companies in the industry to offer a full service
marketing capability and the ability to handle larger and more complex campaigns
for clients.'
-ENDS-
Enquiries:
Adventis Group Plc
Charles Phillpot, CEO Tel: 020 7034 4750
Peter Linnell, Finance Director Tel: 020 7034 4795
Adventis Financial PR
Chris Steele Tel: 020 7034 4759
Tarquin Edwards Tel: 020 7034 4758
Editor's Note:
Adventis Group plc provides a complete range of communications services,
including corporate identity programmes, advertising campaigns, media and
planning and buying, literature, public relations, packaging, exhibitions,
research and planning, interiors signage and digital media. The group employs
c.150 staff in London and the southeast.
Adventis has three divisions focusing on providing a range of services to the
property, healthcare and financial sectors. Adventis Group was admitted to AIM
in 2004.
www.adventis.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.